0000000000-20-011490.txt : 20201231 0000000000-20-011490.hdr.sgml : 20201231 20201202094700 ACCESSION NUMBER: 0000000000-20-011490 CONFORMED SUBMISSION TYPE: UPLOAD PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20201202 FILED FOR: COMPANY DATA: COMPANY CONFORMED NAME: Kinnate Biopharma Inc. CENTRAL INDEX KEY: 0001797768 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824566526 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: UPLOAD BUSINESS ADDRESS: STREET 1: 11975 EL CAMINO REAL, STE 101 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 8582994699 MAIL ADDRESS: STREET 1: 11975 EL CAMINO REAL, STE 101 CITY: SAN DIEGO STATE: CA ZIP: 92130 LETTER 1 filename1.pdf begin 644 filename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end TEXT-EXTRACT 2 filename2.txt United States securities and exchange commission logo December 1, 2020 Nima M. Farzan President and Chief Executive Officer Kinnate Biopharma Inc. 11875 El Camino Real, Suite 101 San Diego, California 92130 Re: Kinnate Biopharma Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed November 30, 2020 File No. 333-250086 Dear Ms. Farzan: We have reviewed your amended registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to the comment, we may have additional comments. Amendment No. 1 to Registration Statement on Form S-1 Use of Proceeds, page 82 1. We reissue comment 2. Revise to state how much of the proceeds of the offer will be used to "initiate and complete [y]our planned Phase 1 clinical trial of KIN002787," how much will be used to "initiate [y]our planned Phase 1 clinical trial of KIN003," what additional funds will be needed to complete the Phase 1 trial of KIN003, and what portion of the proceeds will go to other RAF product candidates, other FGFR product candidates, and other uses. Nima M. Farzan FirstName LastNameNima Kinnate Biopharma Inc. M. Farzan Comapany1, December NameKinnate 2020 Biopharma Inc. December Page 2 1, 2020 Page 2 FirstName LastName You may contact Julie Sherman at (202) 551-3640 or Angela Connell at (202) 551- 3426 if you have questions regarding the financial statements and related matters. Please contact Abby Adams at (202) 551-6902 or Celeste Murphy at (202) 551-3257 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Tony Jeffries, Esq.